Oh Seul Ki, Ko Chang Seok, Jeong Seong-A, Yook Jeong Hwan, Yoo Moon-Won, Kim Beom Su, Lee In-Seob, Gong Chung Sik, Min Sa-Hong, Kim Na Young
Department of Stomach Surgery, Asan Medical Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
J Gastric Cancer. 2023 Jul;23(3):499-508. doi: 10.5230/jgc.2023.23.e28.
Despite scientific evidence regarding laparoscopic gastrectomy (LG) for advanced gastric cancer treatment, its application in patients receiving neoadjuvant chemotherapy remains uncertain.
We used the 2019 Korean Gastric Cancer Association nationwide survey database to extract data from 489 patients with primary gastric cancer who received neoadjuvant chemotherapy. After propensity score matching analysis, we compared the surgical outcomes of 97 patients who underwent LG and 97 patients who underwent open gastrectomy (OG). We investigated the risk factors for postoperative complications using multivariate analysis.
The operative time was significantly shorter in the OG group. Patients in the LG group had significantly less blood loss than those in the OG group. Hospital stay and overall postoperative complications were similar between the two groups. The incidence of Clavien-Dindo grade ≥3 complications in the LG group was comparable with that in the OG group (1.03% vs. 4.12%, P=0.215). No statistically significant difference was observed in the number of harvested lymph nodes between the two groups (38.60 vs. 35.79, P=0.182). Multivariate analysis identified body mass index (odds ratio [OR], 1.824; 95% confidence interval [CI], 1.029-3.234; P=0.040) and extent of resection (OR, 3.154; 95% CI, 1.084-9.174; P=0.035) as independent risk factors for overall postoperative complications.
Using a large nationwide multicenter survey database, we demonstrated that LG and OG had comparable short-term outcomes in patients with gastric cancer who received neoadjuvant chemotherapy.
尽管有关于腹腔镜胃癌切除术(LG)用于晚期胃癌治疗的科学证据,但其在接受新辅助化疗的患者中的应用仍不确定。
我们使用2019年韩国胃癌协会全国调查数据库,从489例接受新辅助化疗的原发性胃癌患者中提取数据。经过倾向评分匹配分析后,我们比较了97例行LG手术的患者和97例行开放胃切除术(OG)的患者的手术结果。我们使用多因素分析研究术后并发症的危险因素。
OG组的手术时间明显更短。LG组患者的失血量明显少于OG组。两组的住院时间和总体术后并发症相似。LG组中Clavien-Dindo≥3级并发症的发生率与OG组相当(1.03%对4.12%,P = 0.215)。两组之间的淋巴结清扫数量没有观察到统计学上的显著差异(38.60对35.79,P = 0.182)。多因素分析确定体重指数(优势比[OR],1.824;95%置信区间[CI],1.029 - 3.234;P = 0.040)和切除范围(OR = 3.154;95% CI,1.084 - 9.174;P = 0.035)是总体术后并发症的独立危险因素。
通过使用一个大型的全国多中心调查数据库,我们证明在接受新辅助化疗的胃癌患者中,LG和OG的短期结果相当。